It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Breast cancer is a global health threat and cases diagnosed in women during the years after childbirth, or postpartum breast cancers (PPBCs), have high risk for metastasis. In preclinical murine models, semaphorin 7a (SEMA7A) drives the metastatic potential of postpartum mammary tumors. Thus, we hypothesize that SEMA7A may drive metastasis of PPBC in women. We report that SEMA7A protein expression is increased in PPBCs compared to their nulliparous counterparts in our University of Colorado cohort. Additionally, tumors from PPBC patients with involved lymph nodes and lymphovascular invasion were higher on average suggesting a potential role for SEMA7A as a prognostic biomarker. Consistent with this hypothesis we identify a level of SEMA7A expression in tumors that can predict for recurrence. We propose SEMA7A as a potential biomarker and therapeutic target for PPBC patients, who currently lack strong predictors of outcome and unique targeted therapy options.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Colorado Cancer Center, Young Women’s Breast Cancer Translational Program, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255); University of Colorado, Anschutz Medical Center, Division of Medical Oncology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
2 University of Colorado School of Public Health, Department of Pediatrics, School of Medicine, and Dept of Biostatistics, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
3 University of Colorado, Anschutz Medical Center, Division of Medical Oncology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
4 University of Colorado Cancer Center, Young Women’s Breast Cancer Translational Program, Aurora, USA (GRID:grid.499234.1) (ISNI:0000 0004 0433 9255); University of Colorado School of Public Health, Department of Epidemiology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)